The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials
BackgroundNon-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease. Research on the efficacy of probiotics, prebiotics, and synbiotics on NAFLD patients continues to be inconsistent. The purpose of this study is to evaluate the effectiveness of these microbial therapies...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Nutrition |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnut.2022.1024678/full |
| _version_ | 1797985711576580096 |
|---|---|
| author | Wenmin Xing Wenyan Gao Xiaoling Lv Zhenlei Zhao Genxiang Mao Xiaoyan Dong Zuyong Zhang |
| author_facet | Wenmin Xing Wenyan Gao Xiaoling Lv Zhenlei Zhao Genxiang Mao Xiaoyan Dong Zuyong Zhang |
| author_sort | Wenmin Xing |
| collection | DOAJ |
| description | BackgroundNon-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease. Research on the efficacy of probiotics, prebiotics, and synbiotics on NAFLD patients continues to be inconsistent. The purpose of this study is to evaluate the effectiveness of these microbial therapies on NAFLD.MethodsEligible randomized-controlled trials reporting the effect of probiotics, prebiotics, or synbiotics in NAFLD were searched in PubMed, Web of Science, Embase, Google scholar, and CNKI databases from 2020 to Jul 2022. The changes in the outcomes were analyzed using standard mean difference (SMD) and 95% confidence intervals (CIs) with a random- or fixed-effects model to examine the effect of microbial therapies. Subgroup analysis, influence and publication bias analysis were also performed. The quality of the eligible studies was evaluated using the Cochrane Risk of Bias Tool.ResultsEleven studies met the inclusion criteria involving 741 individuals. Microbial therapies could improve liver steatosis, total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL-c), alanine aminotransferase (ALT), alkaline phosphatase (ALP), glutamyl transpeptidase (GGT), and homeostasis model assessment-insulin resistance (HOMAI-R) (all P < 0.05). But microbial therapies could not ameliorate body mass index (BMI), energy, carbohydrate, fat intake, fasting blood sugar, HbA1c, insulin, high-sensitivity C-reactive protein (hs-CRP), and hepatic fibrosis of patients with NAFLD.ConclusionProbiotics, prebiotics, and synbiotics supplementation can potentially improve liver enzymes, lipid profiles, and liver steatosis in patients with NAFLD. |
| first_indexed | 2024-04-11T07:22:25Z |
| format | Article |
| id | doaj.art-b5a3b4f1f7fe46b4a32c956dd4a732ca |
| institution | Directory Open Access Journal |
| issn | 2296-861X |
| language | English |
| last_indexed | 2024-04-11T07:22:25Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Nutrition |
| spelling | doaj.art-b5a3b4f1f7fe46b4a32c956dd4a732ca2022-12-22T04:37:10ZengFrontiers Media S.A.Frontiers in Nutrition2296-861X2022-10-01910.3389/fnut.2022.10246781024678The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trialsWenmin Xing0Wenyan Gao1Xiaoling Lv2Zhenlei Zhao3Genxiang Mao4Xiaoyan Dong5Zuyong Zhang6Zhejiang Provincial Key Laboratory of Geriatrics, Department of Geriatrics, Zhejiang Hospital, Hangzhou, ChinaSchool of Pharmacy, Hangzhou Medical College, Hangzhou, ChinaZhejiang Provincial Key Laboratory of Geriatrics, Department of Geriatrics, Zhejiang Hospital, Hangzhou, ChinaZhejiang Provincial Key Laboratory of Geriatrics, Department of Geriatrics, Zhejiang Hospital, Hangzhou, ChinaZhejiang Provincial Key Laboratory of Geriatrics, Department of Geriatrics, Zhejiang Hospital, Hangzhou, ChinaCollege of Pharmacy and Traditional Chinese Medicine, Jiangsu College of Nursing, Huaian, ChinaThe Third People’s Hospital of Hangzhou, Hangzhou, ChinaBackgroundNon-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease. Research on the efficacy of probiotics, prebiotics, and synbiotics on NAFLD patients continues to be inconsistent. The purpose of this study is to evaluate the effectiveness of these microbial therapies on NAFLD.MethodsEligible randomized-controlled trials reporting the effect of probiotics, prebiotics, or synbiotics in NAFLD were searched in PubMed, Web of Science, Embase, Google scholar, and CNKI databases from 2020 to Jul 2022. The changes in the outcomes were analyzed using standard mean difference (SMD) and 95% confidence intervals (CIs) with a random- or fixed-effects model to examine the effect of microbial therapies. Subgroup analysis, influence and publication bias analysis were also performed. The quality of the eligible studies was evaluated using the Cochrane Risk of Bias Tool.ResultsEleven studies met the inclusion criteria involving 741 individuals. Microbial therapies could improve liver steatosis, total cholesterol (TC), triglyceride (TG), low-density lipoprotein (LDL-c), alanine aminotransferase (ALT), alkaline phosphatase (ALP), glutamyl transpeptidase (GGT), and homeostasis model assessment-insulin resistance (HOMAI-R) (all P < 0.05). But microbial therapies could not ameliorate body mass index (BMI), energy, carbohydrate, fat intake, fasting blood sugar, HbA1c, insulin, high-sensitivity C-reactive protein (hs-CRP), and hepatic fibrosis of patients with NAFLD.ConclusionProbiotics, prebiotics, and synbiotics supplementation can potentially improve liver enzymes, lipid profiles, and liver steatosis in patients with NAFLD.https://www.frontiersin.org/articles/10.3389/fnut.2022.1024678/fullnon-alcoholic fatty liver diseaseprobioticsprebioticsliver enzymeslipid profileresistance |
| spellingShingle | Wenmin Xing Wenyan Gao Xiaoling Lv Zhenlei Zhao Genxiang Mao Xiaoyan Dong Zuyong Zhang The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials Frontiers in Nutrition non-alcoholic fatty liver disease probiotics prebiotics liver enzymes lipid profile resistance |
| title | The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials |
| title_full | The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials |
| title_fullStr | The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials |
| title_full_unstemmed | The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials |
| title_short | The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials |
| title_sort | effects of supplementation of probiotics prebiotics or synbiotics on patients with non alcoholic fatty liver disease a meta analysis of randomized controlled trials |
| topic | non-alcoholic fatty liver disease probiotics prebiotics liver enzymes lipid profile resistance |
| url | https://www.frontiersin.org/articles/10.3389/fnut.2022.1024678/full |
| work_keys_str_mv | AT wenminxing theeffectsofsupplementationofprobioticsprebioticsorsynbioticsonpatientswithnonalcoholicfattyliverdiseaseametaanalysisofrandomizedcontrolledtrials AT wenyangao theeffectsofsupplementationofprobioticsprebioticsorsynbioticsonpatientswithnonalcoholicfattyliverdiseaseametaanalysisofrandomizedcontrolledtrials AT xiaolinglv theeffectsofsupplementationofprobioticsprebioticsorsynbioticsonpatientswithnonalcoholicfattyliverdiseaseametaanalysisofrandomizedcontrolledtrials AT zhenleizhao theeffectsofsupplementationofprobioticsprebioticsorsynbioticsonpatientswithnonalcoholicfattyliverdiseaseametaanalysisofrandomizedcontrolledtrials AT genxiangmao theeffectsofsupplementationofprobioticsprebioticsorsynbioticsonpatientswithnonalcoholicfattyliverdiseaseametaanalysisofrandomizedcontrolledtrials AT xiaoyandong theeffectsofsupplementationofprobioticsprebioticsorsynbioticsonpatientswithnonalcoholicfattyliverdiseaseametaanalysisofrandomizedcontrolledtrials AT zuyongzhang theeffectsofsupplementationofprobioticsprebioticsorsynbioticsonpatientswithnonalcoholicfattyliverdiseaseametaanalysisofrandomizedcontrolledtrials AT wenminxing effectsofsupplementationofprobioticsprebioticsorsynbioticsonpatientswithnonalcoholicfattyliverdiseaseametaanalysisofrandomizedcontrolledtrials AT wenyangao effectsofsupplementationofprobioticsprebioticsorsynbioticsonpatientswithnonalcoholicfattyliverdiseaseametaanalysisofrandomizedcontrolledtrials AT xiaolinglv effectsofsupplementationofprobioticsprebioticsorsynbioticsonpatientswithnonalcoholicfattyliverdiseaseametaanalysisofrandomizedcontrolledtrials AT zhenleizhao effectsofsupplementationofprobioticsprebioticsorsynbioticsonpatientswithnonalcoholicfattyliverdiseaseametaanalysisofrandomizedcontrolledtrials AT genxiangmao effectsofsupplementationofprobioticsprebioticsorsynbioticsonpatientswithnonalcoholicfattyliverdiseaseametaanalysisofrandomizedcontrolledtrials AT xiaoyandong effectsofsupplementationofprobioticsprebioticsorsynbioticsonpatientswithnonalcoholicfattyliverdiseaseametaanalysisofrandomizedcontrolledtrials AT zuyongzhang effectsofsupplementationofprobioticsprebioticsorsynbioticsonpatientswithnonalcoholicfattyliverdiseaseametaanalysisofrandomizedcontrolledtrials |